ARTICLE | Preclinical News
Histone modifier is implicated in epithelial-mesenchymal transition
December 11, 2017 2:02 PM UTC
In a paper published in the Journal of Cell Biology, researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) identified a histone modifier that may regulate epithelial-mesenchymal transition (EMT), a process associated with tumor cell invasiveness and chemotherapy resistance.
The Genentech team, led by VP of Cancer Immunology Ira Mellman, sought to identify epigenetic regulators of EMT...
BCIQ Company Profiles